|
|
Volumn 24, Issue 10, 2002, Pages 783-787
|
|
The SOGC statement on the WHI report on estrogen and progestin use in postmenopausal women
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CONJUGATED ESTROGEN;
CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE;
MEDROXYPROGESTERONE ACETATE;
AGED;
ARTICLE;
BREAST TUMOR;
CARDIOVASCULAR DISEASE;
DRUG COMBINATION;
DRUG EFFECT;
ESTROGEN THERAPY;
EVIDENCE BASED MEDICINE;
FEMALE;
HUMAN;
INFORMED CONSENT;
METHODOLOGY;
MIDDLE AGED;
PATIENT EDUCATION;
PATIENT SELECTION;
POSTMENOPAUSE;
POSTMENOPAUSE OSTEOPOROSIS;
PRACTICE GUIDELINE;
RISK;
RISK FACTOR;
STANDARD;
WOMEN'S HEALTH;
AGED;
BREAST NEOPLASMS;
CARDIOVASCULAR DISEASES;
DRUG COMBINATIONS;
ESTROGEN REPLACEMENT THERAPY;
ESTROGENS, CONJUGATED (USP);
EVIDENCE-BASED MEDICINE;
FEMALE;
HUMANS;
INFORMED CONSENT;
MEDROXYPROGESTERONE 17-ACETATE;
MIDDLE AGED;
OSTEOPOROSIS, POSTMENOPAUSAL;
PATIENT EDUCATION;
PATIENT SELECTION;
POSTMENOPAUSE;
RISK;
RISK FACTORS;
WOMEN'S HEALTH;
|
|
EID: 0036781218
PISSN: 17012163
EISSN: None
Source Type: Journal
DOI: 10.1016/S1701-2163(16)30471-6 Document Type: Article |
|
Times cited : (22)
|
|
References (0)
|